Does Mounjaro Make You Constipated?

What the trial data actually showed about constipation

In the SURMOUNT-1 trial (the pivotal 72-week study of tirzepatide in adults with obesity, published in the New England Journal of Medicine) constipation was reported by a meaningful proportion of participants across all active dose groups, and it was consistently more common than in the placebo arm. The signal was present from the earliest weeks. That pattern is consistent with what the NHS now documents in its tirzepatide patient information: constipation sits alongside nausea, diarrhoea and indigestion as part of the characteristic gastrointestinal profile of this drug class.

Why does Mounjaro make you constipated at all? Tirzepatide activates both GIP and GLP-1 receptors, and one of the downstream effects is slower gastric emptying. Food moves through the digestive tract more gradually, which is part of how the medicine supports appetite reduction and blood-sugar control. The same mechanism means the colon receives its contents more slowly, and transit time lengthens, which is the physiological basis for why people find themselves constipated on Mounjaro and not a sign that something has gone wrong; it is a predictable extension of how the medicine works.

The effect is dose-related in tendency. Many people find it most noticeable after moving from 2.5mg to 5mg, or at later dose increases. Some experience it only transiently; others find it settles into a mild, manageable pattern; a smaller group find it persists and worth discussing with their prescriber before the next step-up. You can read more about who is most likely to experience constipation on Mounjaro and what the evidence says about duration.

Practical steps that may help, and what your prescriber needs to know

Hydration is the first lever. Mounjaro suppresses appetite, which can inadvertently suppress fluid intake too; deliberate drinking throughout the day supports normal gut motility. Dietary fibre (vegetables, pulses, whole grains) helps, though adding large amounts suddenly can worsen bloating in the early weeks, so a gradual increase tends to work better. Regular movement, even a brisk daily walk, can encourage motility. These are general healthy-living measures that complement treatment; they are not a substitute for clinical advice tailored to you.

If over-the-counter options such as a bulk-forming laxative are something you are considering, discuss this with a pharmacist or your prescriber first. Some people find osmotic laxatives helpful; others find they are not needed once the adjustment period passes. The point is not to manage this alone if it is significantly affecting your quality of life. Tirzepatide is a prescription medicine, and the people who prescribed it to you should know if a side effect is causing meaningful difficulty. That is exactly what aftercare support is for.

If constipation is accompanied by significant abdominal discomfort, bloating, or changes in your appetite beyond what feels proportionate, it is worth documenting and raising with your prescriber. For those wondering why constipation can feel more severe at certain points on Mounjaro, dose timing and recent dietary changes are usually the first things to examine.

When constipation on Mounjaro is a red flag, and when to get medical help

Ordinary constipation on Mounjaro is uncomfortable but not dangerous. However, the MHRA's Drug Safety Update issued in January 2026 for GLP-1 medicines flagged acute pancreatitis as an infrequent but serious risk: the key warning sign is severe stomach pain that spreads to the back, with or without vomiting. This is not constipation and should not be waited out. Seek urgent medical attention if you experience it.

Other situations that go beyond routine management: constipation so severe that you have not passed a stool for many days and are experiencing significant pain or distension; signs of dehydration such as very dark urine, dizziness, or a rapid heartbeat (sometimes a consequence of severe GI upset in either direction); or any sudden change in bowel habit that does not fit the expected pattern. These are signals to contact a healthcare professional promptly, not after the next routine review.

You can report any suspected side effect (whether or not you are certain it is connected to Mounjaro) via the MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk. This includes constipation if it is severe or unexpected in character. Yellow Card reports help the MHRA monitor the safety profile of medicines as real-world use grows, and tirzepatide carries the Black Triangle (▼) status, meaning enhanced post-authorisation surveillance is ongoing. The broader safety profile of tirzepatide in the UK context is covered on our pages examining specific side effects in detail.

How this fits into a clinically supervised treatment plan

Managing side effects well is one of the clearest differences between a supervised treatment and a DIY approach. When you consult with a GPhC-registered prescriber at a regulated service, they know which side effects are expected, which are worth monitoring, and which warrant a pause or a slower titration. Constipation that feels unmanageable is not a reason to stop without advice, it may be a reason to hold a dose increase for a few extra weeks, adjust diet, or review hydration habits with clinical input.

Mounjaro is one of several weight-management options available through a regulated private prescription. If you want to understand whether it is clinically suitable for you, and to have a frank conversation about the side effects you are most concerned about, our prescribers cover exactly that in the consultation. No assumption that you will proceed; just a real clinical conversation. You can also read the broader Mounjaro treatment overview or explore general weight-loss treatment options before deciding whether to go further.